# US 2026/0098088 A1 · Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098088 A1
- Document ID: US20260098088A1
- Status: Published application
- Kind: A1
- Application number: 19/399,067
- Filed: 2025-11-24
- Published: 2026-04-09
- Earliest claimed: 2020-05-13
- Assignees: Disc Medicine, Inc.; AbbVie Inc.; AbbVie Deutschland GmbH & Co. KG
- Applicants: Disc Medicine, Inc.; AbbVie Inc.; AbbVie Deutschland GmbH & Co. KG
- Inventors: Maria Beconi; John Quisel; Brian MacDonald; Steven Robinette; Bernhard Mueller; Andreas Popp; Jennifer M. Perez
- Web page: https://patentgrep.com/patent/US20260098088A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.

## Claims

### Claim at position 1

1-52. (canceled)

### Claim 53

A method of treating anemia in a subject having myelofibrosis, the method comprising: administering to the subject every 4 weeks or once every month a composition comprising an isolated antibody that binds to human hemojuvelin (HJV) and a pharmaceutically acceptable carrier, wherein the isolated antibody comprise: a heavy chain comprising the amino acid sequence of SEQ ID NO: 117, and a light chain comprising the amino acid sequence of SEQ ID NO: 62.

### Claim 54 (depends on 53)

The method of claim 53, wherein the composition is administered to the subject parenterally.

### Claim 55 (depends on 53)

The method of claim 53, wherein the composition is administered to the subject via subcutaneous injection.

### Claim 56 (depends on 53)

The method of claim 53, wherein the composition is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg.

### Claim 57 (depends on 53)

The method of claim 53, wherein the subject is erythrocyte transfusion-independent.

### Claim 58 (depends on 53)

The method of claim 53, wherein the subject has previously received or is receiving a JAK-STAT inhibitor, wherein the JAK-STAT inhibitor is momelotininb, ruxolitinib, fedratinib, pacritinib, INCB039110, AG490, or PpYLKTK.

### Claim 59 (depends on 53)

The method of claim 53, wherein the subject has previously received or is receiving an erythropoietin stimulating agent, wherein the erythropoietin stimulating agent is danazol, prednisone, thalidomide, lenalidomide, or pomalidomide.

### Claim 60 (depends on 53)

The method of claim 53, wherein the subject has previously received or is receiving a growth factor ligand trap, wherein the growth factor ligand trap is sotatercept or luspatercept.

### Claim 61 (depends on 53)

The method of claim 53, wherein the subject has a transferrin saturation percentage (TSAT %) that is less than 75%.

### Claim 62 (depends on 53)

The method of claim 53, wherein the administration of the isolated antibody results in a decrease in circulating hepcidin-25 concentration and/or increase serum TSAT % that persist for a period of time, wherein the period of time is one month or more.

### Claim 63 (depends on 53)

The method of claim 53, wherein the administration of the isolated antibody treats one or more symptoms or complications of myelofibrosis-associated anemia selected from inflammation, bone marrow failure, splenomegaly, hypercatabolic symptoms, and/or fatigue.

### Claim 64

A method of treating anemia in a subject having myelofibrosis, the method comprising: administering to the subject every 4 weeks or once every month a composition comprising an isolated antibody that binds to human hemojuvelin (HJV) and a pharmaceutically acceptable carrier, wherein the isolated antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 62.

### Claim 65 (depends on 64)

The method of claim 64, wherein the composition is administered to the subject via subcutaneous injection.

### Claim 66 (depends on 64)

The method of claim 64, wherein the composition is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg.

### Claim 67 (depends on 64)

The method of claim 64, wherein the subject is erythrocyte transfusion-independent.

### Claim 68 (depends on 64)

The method of claim 64, wherein the subject has previously received or is receiving a JAK-STAT inhibitor, wherein the JAK-STAT inhibitor is momelotininb, ruxolitinib, fedratinib, pacritinib, INCB039110, AG490, or PpYLKTK.

### Claim 69 (depends on 64)

The method of claim 64, wherein the subject has previously received or is receiving an erythropoietin stimulating agent, wherein the erythropoietin stimulating agent is danazol, prednisone, thalidomide, lenalidomide, or pomalidomide.

### Claim 70 (depends on 64)

The method of claim 64, wherein the subject has previously received or is receiving a growth factor ligand trap, wherein the growth factor ligand trap is sotatercept or luspatercept.

### Claim 71 (depends on 64)

The method of claim 64, wherein the subject has a transferrin saturation percentage (TSAT %) that is less than 75%.

### Claim 72 (depends on 64)

The method of claim 64, wherein the administration of the isolated antibody results in a decrease in circulating hepcidin-25 concentration and/or increase serum TSAT % that persist for a period of time, wherein the period of time is one month or more.

### Claim 73

A method of treating anemia in a subject having myelofibrosis, the method comprising administering to the subject every 4 weeks or once every month an effective amount of a composition comprising:
(i) an isolated anti-human hemojuvelin (HJV) antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain comprising the amino acid sequence of SEQ ID NO: 62;
(ii) an isolated anti-human hemojuvelin (HJV) antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 117, and a light chain comprising the amino acid sequence of SEQ ID NO: 62,
(iii) an isolated anti-human HJV antibody comprising a heavy chain that comprises the amino acid sequence of SEQ ID NO: 131, and a light chain that comprises the amino acid sequence of SEQ ID NO: 62; and/or
(iv) an isolated anti-human HJV antibody comprising a heavy chain that comprises the amino acid sequence of SEQ ID NO: 130, and a light chain that comprises the amino acid sequence of SEQ ID NO: 62;
wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 74 (depends on 73)

The method of claim 73, wherein the composition is administered to the subject via subcutaneous injection.

### Claim 75 (depends on 73)

The method of claim 73, wherein the composition is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg.

### Claim 76 (depends on 73)

The method of claim 73, wherein the subject is erythrocyte transfusion-independent.

### Claim 77 (depends on 73)

The method of claim 73, wherein the subject has previously received or is receiving a JAK-STAT inhibitor, wherein the JAK-STAT inhibitor is momelotininb, ruxolitinib, fedratinib, pacritinib, INCB039110, AG490, or PpYLKTK.

### Claim 78 (depends on 73)

The method of claim 73, wherein the subject has previously received or is receiving an erythropoietin stimulating agent, wherein the erythropoietin stimulating agent is danazol, prednisone, thalidomide, lenalidomide, or pomalidomide.

### Claim 79 (depends on 73)

The method of claim 73, wherein the subject has previously received or is receiving a growth factor ligand trap, wherein the growth factor ligand trap is sotatercept or luspatercept.

### Claim 80 (depends on 73)

The method of claim 73, wherein the subject has a transferrin saturation percentage (TSAT %) that is less than 75%.

### Claim 81 (depends on 73)

The method of claim 73, wherein the administration of the composition results in a decrease in circulating hepcidin-25 concentration and/or increase serum TSAT % that persist for a period of time, wherein the period of time is one month or more.

### Claim 82 (depends on 73)

The method of claim 73, wherein the administration of the composition treats one or more symptoms or complications of myelofibrosis-associated anemia selected from inflammation, bone marrow failure, splenomegaly, hypercatabolic symptoms, and/or fatigue.
